



## Preferred Drug List

### NEW DRUG REVIEW

**Proprietary Name:** Nucynta™

**Common Name:** Tapentadol

**PDL Category:** Narcotics-Miscellaneous

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Tramadol	Preferred
Oxycodone	Preferred

#### Summary

**Indications and Usage:** Treatment of moderate to severe acute pain in patients 18 years of age and older.<sup>1</sup>

**Mechanism of Action:** Exact mechanism of action is unknown. Analgesic efficacy is thought to be due to mu-opioid agonist activity and the inhibition of norepinephrine reuptake.<sup>1</sup>

**Dosage Forms:** Tablets: 50mg, 75mg, 100mg

**Recommended Dosage:** 50 mg, 75 mg, or 100 mg every 4 to 6 hours depending upon pain intensity.<sup>1</sup>

**Common Adverse Drug Reactions:** Dizziness, nausea, vomiting, somnolence.<sup>1</sup>

**Contraindications:** Impaired pulmonary function. Paralytic ileus. Concomitant use with monoamine oxidase inhibitors (MAOI) or use within 14 days.<sup>1</sup>

**Manufacturer:** Janssen Ortho, LLC

**Analysis:** Nucynta™ is a new centrally acting oral analgesic indicated for the treatment of moderate to severe acute pain in adult patients. In the trials used to gain FDA approval, Nucynta™ was compared only to placebo for the treatment of pain post bunionectomy and pain from end-stage joint disease. An additional study concluded Nucynta™ was as effective as immediate release oxycodone for the treatment of back pain or osteoarthritis pain of the hip or knee and offered improved gastrointestinal tolerability. Preferred alternatives appear on the Preferred Drug List, which have similar clinical efficacy and are more cost effective. Therefore, it is recommended that Nucynta™ be added to the Preferred Drug List as a non-preferred drug.

**IME Recommendation:**

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input checked="" type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	

1. Nucynta™ [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2009.